Merck Invested in New KRAS G12D Cancer Therapy
Merck has secured rights to a potential KRAS inhibitor, a target found in many pancreatic cancers.
Updated on Oct. 3, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies' high-cost investments in unproven cancer treatments prioritize patient outcomes?
Merck recently acquired the rights to a KRAS G12D inhibitor from Cyrum Therapeutics for $2.13 billion to advance cancer research. This move targets proteins that drive cell growth in approximately 40% of patients with pancreatic ductal adenocarcinoma.
Why it matters
KRAS mutations are major drivers of cancer cell growth, yet no treatments specifically targeting the G12D mutation have received final regulatory approval. This investment reflects a broader industry push to find therapies for these previously difficult-to-treat protein structures.
Industry investment in KRAS G12D inhibitors has reached billions, including a $2.13 billion deal by Merck, while similar efforts by Bristol Myers Squibb and AstraZeneca have faced development setbacks. No treatments for this mutation have yet cleared the final regulatory hurdle.
The players
Merck
A global pharmaceutical company that develops treatments for oncology, infectious diseases, and diabetes.
Bayer
A life sciences company with a focus on pharmaceuticals and medical diagnostics for oncology and cardiovascular health.
Cyrum Therapeutics
A biotechnology firm that develops targeted cancer therapies based in China.
Revolution Medicines
A clinical-stage oncology company focused on developing inhibitors that target RAS-addicted cancers.
Johnson & Johnson
A multinational health corporation that produces medical devices and pharmaceuticals including oncology therapies.
The details
The target, KRAS G12D, is a protein structure notoriously difficult for drugs to bind to effectively. Researchers are now using advanced design technologies and protein degraders, which work by recruiting the body's natural cellular systems to identify and eliminate the harmful target proteins entirely. This approach seeks to bypass the variability that led other companies to discontinue their own development programs.
Timeline
1982: The KRAS mutation was first discovered.
August 2025: Bayer acquired a KRAS G12D inhibitor.
June 2026: Johnson & Johnson acquired Firefly Bio, and Zoldeunsip entered Phase 3 trials.
September 28, 2026: Merck acquired rights from Cyrum Therapeutics.
Health Landscape
The pursuit of KRAS-targeted treatments represents one of the most active frontiers in modern oncology research. This acquisition follows the industry-wide pattern of aggressively investing in the development of KRAS-targeted cancer therapies to fill a significant gap in treatment.
While these developments signal potential new avenues for treatment in the future, there are currently no approved therapies specifically for the KRAS G12D mutation. Patients managing pancreatic cancer should discuss their specific genetic test results and any relevant clinical trial options with their physician.
The takeaway
The race to develop drugs targeting the KRAS mutation remains a high-stakes, rapidly evolving area of medical research. If you or a loved one are facing a cancer diagnosis, ask your oncologist if molecular profiling or clinical trial participation is appropriate for your specific case.
Further reading
For more on evolving research, visit our Cancer section.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust that pharmaceutical companies' high-cost investments in unproven cancer treatments prioritize patient outcomes?
